Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-01-18
2004-04-27
Fay, Zohreh (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
Reexamination Certificate
active
06727284
ABSTRACT:
FIELD OF INVENTION
The present invention relates to the field of cardiovascular disease and more particularly, the treatment and prevention of poor cardiac function following surgery, including, but not limited to, open heart surgery.
BACKGROUND
Poor cardiac function remains a significant problem in the post-operative period, such as the period following open heart surgery. Drugs used to treat this type of cardiac dysfunction have either forced the heart to work harder (e.g. inotropes), or decreased the work load faced by the heart (e.g. vasodilators, alpha, beta and calcium channel blockers). Unfortunately, both classes of drugs have deleterious side-effects.
For example, one of the most common inotropes used to improve cardiac function is digitalis. However, the dosage of digitalis is critical: intoxication can be fatal. While the overall level of toxicity is not clear, it has been estimated that approximately 25% of hospitalized patients taking digitalis show some signs of toxicity. See Beller et al., “Digitalis intoxication: A prospective clinical study with serum level correlations.”
N. Engl. J. Med.
284:989 (1971).
Calcium channel blockers also have side-effects. Some, for example, are reported to aggravate myocardial ischemia. This may be due to excessive hypotension or decreased coronary perfusion. See Goodman and Gilman's
The Pharmacological Basis of Therapeutics
(Pergamon Press. Eighth Edition 1990) (pgs. 774-779). While the drug verapamil is less likely to have this problem, the use of the drug is limited. Indeed, it is specifically contraindicated where there are SA or AV nodal conduction disturbances.
What is needed is a safe and effective pharmacological approach to the treatment and prevention of cardiac failure. Such a treatment should permit broad use without significant side-effects.
SUMMARY OF THE INVENTION
The present invention relates to the field of cardiovascular disease and more particularly, the treatment and prevention of poor cardiac function following an ischemic incident, a heart attack, or surgery. With regard to surgery, the procedure can be used before, during and following surgery, and the surgery can be general surgery (e.g., transplantation, such as liver transplantation) or cardiac surgery, such cardiac surgery including, but not limited to, open heart surgery. The present invention relates to new methods of treating poor cardiac performance, such as that resulting from ischemia in a surgical setting. In some embodiments, a patient with a myocardial infarction (e.g., due to occlusion of a coronary artery) is treated by the methods of the present invention.
Both treatment and prevention are contemplated. In one embodiment, the present invention contemplates a method comprising the steps of a) providing: i) a subject having symptoms of poor cardiac performance and ii) means for delivering a solution of dichloroacetate; and b) delivering said solution to said subject with said delivering means under conditions such that said subject has a blood (e.g. serum or plasma) concentration of dichloroacetate in the therapeutic range (such as a concentration of approximately 0.5 mM or greater). In another embodiment, the present invention contemplates a method comprising the steps of a) providing: i) a subject at risk of poor cardiac performance and ii) means for delivering a solution of dichloroacetate; and b) delivering said solution to said subject with said delivering means under conditions such that said subject has a blood (e.g. serum or plasma) concentration of dichloroacetate of greater than approximately 200 &mgr;M, more preferably greater than 500 &mgr;M, and still more preferably greater than 1 mM, for a period of time longer than 1 hour, and more preferably longer than 6 hours, and most preferably 24 hours or longer. In one embodiment, said delivering of step (b) is performed where the conditions comprise a first administration, comprising a bolus, and a second administration, wherein said second administration comprises continuous administration.
It is not intended that the invention be limited to subjects with any one type of symptom of poor cardiac function. Also, the age, sex, or degree of disease state is not intended to be in any way limiting to the present invention, although the invention can be used with particular success on children and infants, including but not limited to neonates.
The invention is also not limited by the cause of poor cardiac function, although the invention can be used with particular success with patients whose cardiac function is poor following surgery, such as open heart surgery. Of course, it is not intended that the present invention be limited to particular surgical procedures. Open heart surgery using cardiopulmonary bypass pump and aortic cross clamp is contemplated as one example of surgery putting patients at risk for poor cardiac function. This includes simple lesions such as a trial septal defect or ventricular septal defect and complex lesions such as transposition arterial switch, Tetralogy of Fallot, atrioventricular septal defect, repair of total veins, Fontan operation, etc. In some embodiments, the methods and composition of the present invention find use in the treatment of myocardial infarction (e.g., during or following thrombolysis). For example, dichloroacetate solution can be supplied during. reperfusion.
While it is not intended that the present invention be limited, by the particular delivery means. One means is an intravenous means, such as that achieved by introduction through an intravenous drip. Other means include (but are not limited to) delivery with a catheter. A preferred means involves direct injection into the aorta.
The particular dosage is also not intended to be limiting. A variety of temporal protocols is contemplated. Delivery in a bolus as well as continuous delivery is contemplated. In a preferred embodiment, dichloroacetate (such as sodium dichloroacetate) is given in a bolus of at least 100 mg/kg of an approximately 100 mg/ml solution (1.0 cc/kg bolus) and, immediately thereafter, dichloroacetate is given as an infusion at approximately 12.5 mg/kg/hr for greater than 10 hours, and more preferably, 24 hours or more.
Higher dosages are permitted. Dichloroacetate does not have significant sideeffects, although some patients experience mild drowsiness.
Definitions
The following definitions are to be used to further explain the invention and should in no way be used to limit the scope of the invention.
“Subject” as used herein refers to a vertebrate. Preferably, the vertebrate is a human.
“Catheter” as used herein refers to a device for insertion into canals, vessels, passageway or body cavities.
“Cardiac disease” as used herein refers to a state in which the heart of a subject is no longer able to function within normal parameters.
“Internally” as used herein refers to the state of being inside the body.
“Temporal protocol” or “dosage regiment” as used herein refers to the time sequence for administration of drug, to i.e. the amount of drug given over time.
REFERENCES:
patent: 5587397 (1996-12-01), Fox
patent: 5643951 (1997-07-01), Stacpoole et al.
patent: WO 99/17763 (1999-04-01), None
Beller, et al., “Digitalis intoxication: A prospective clinical study with serum level correlations.”N. Engl. J. Med. 284:989 (1971).
Bing, et al, “Metabolic studies on the human heart in vivo. Studies on carbohydrate metabolism of the human heart,”Am. J. Med. 15:284 (1953).
Collins-Nakai, et al., “Dichloroacetic acid (DCA) after open heart surgery in infants and children,” Cad. J. Cardiol 11(suppl. E):106E (1995).
Goodman and Gilman'sThe Pharmacological Basis of Therapeutics(Pergamon Press. Eight Edition 1990) (pp. 774-779).
Lopaschuk, et al., “Etomoxir, a carnitine palmitoyltransferase I inhibitor, protects hearts from fatty acid-induced ischemic injury independent of changes in long chain acylarnitine,”Circ. Res. 63:1036 (1988).
Lopaschuk, et al., “Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia,”Ci
Collins-Nakai Ruth
Dyck Jason R. B.
Lopaschuk Gary
Teo Koon
Delacroix-Muirheid C.
Fay Zohreh
Pillsbury & Winthrop LLP
University of Alberta
LandOfFree
Postsurgical treatment with dichloroacetate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Postsurgical treatment with dichloroacetate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Postsurgical treatment with dichloroacetate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3205940